Unlike
any other vaccine designed for human use, this product would be a DNA vaccine that only contains a particular part of the pathogen (rather than a vaccine with an inactivated live or dead virus, for example).
Not exact matches
Friedman and his team, therefore,
designed their new
vaccine to induce an immune response against not only gD2 but also two
other viral glycoproteins, gC2 and gE2.
The same strategy might aid efforts to
design vaccines against
other viruses, researchers said.
The team is now readying the
vaccine for human trials and is
designing related
vaccines to treat
other autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease.
However, bnAbs are found in only a minority of infected people, in quantities too small to clear the virus, so Burton and
other researchers are now trying to
design vaccines to elicit these bnAbs in numbers large enough to provide effective protection.
«It is likely to be part of the mechanism for changing the functions of
other immune cells, and the insight may help in
designing vaccines.»
The ability to
design new protein nanostructures could have useful implications in targeted delivery of drugs, in
vaccine development and in plasmonics — manipulating electromagnetic signals to guide light diffraction for information technologies, energy production or
other uses.
«The immune response and the safety so far have put these out there further than the
other candidates we have,» says infectious disease specialist Scott Hammer of Columbia University, part of the team
designing the VRC
vaccine trial.
For 30 years, researchers have struggled to determine which immune responses best foil HIV, information that has guided the
design of AIDS
vaccines and
other prevention approaches.
Other questions remain about how best to
design and deliver neoantigen
vaccines.
This is a very exciting discovery as it offers numerous possibilities of
designing therapies and
vaccines to target these exposed surfaces to treat dengue as well as
other related viruses such as Zika and chikungunya.
The engineer has
designed air - purifying plants, edible bottles and
vaccine technologies to deliver drugs to the lungs to eliminate injections, among
other inventions.
Dr. Schief's work focuses on computation - guided and structure - based
design of immunogens and immunization regimens, with the goal of inducing broadly neutralizing antibodies against HIV and
other pathogens that have frustrated traditional
vaccine design strategies.
Many researchers at NIH, universities and medical schools are looking for antibodies that act on a broad range of flu strains, with the goal of understanding how they attach to the viruses and then
designing vaccines or
other flu therapies that produce a similar effect.
In the years since the rabies
vaccine, many
other canine vaccinations were developed, specifically
designed to prevent diseases like distemper, parvovirus, canine hepatitis, parainfluenza, Bordetella (kennel cough), Lyme disease, leptospirosis, and canine influenza.
WHAT IS STILL UNKNOWN Prevalence of FISS Published estimates on the prevalence of FISS vary significantly, depending on the study
design, numbers of cats in the study, geographic location of the cats, and the fact that injections
other than
vaccines are known to induce sarcomas.